A detailed history of Parallel Advisors, LLC transactions in Siga Technologies Inc stock. As of the latest transaction made, Parallel Advisors, LLC holds 3,596 shares of SIGA stock, worth $23,194. This represents 0.0% of its overall portfolio holdings.

Number of Shares
3,596
Previous 223 1512.56%
Holding current value
$23,194
Previous $1,000 2300.0%
% of portfolio
0.0%
Previous 0.0%

Shares

16 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

BUY
$6.74 - $11.97 $22,734 - $40,374
3,373 Added 1512.56%
3,596 $24,000
Q1 2024

May 06, 2024

BUY
$4.51 - $8.92 $825 - $1,632
183 Added 457.5%
223 $1,000
Q4 2023

Feb 09, 2024

SELL
$4.82 - $6.25 $4,689 - $6,081
-973 Reduced 96.05%
40 $0
Q3 2023

May 20, 2024

BUY
$4.32 - $5.77 $4,047 - $5,406
937 Added 1232.89%
1,013 $5,000
Q3 2023

Nov 13, 2023

BUY
$4.32 - $5.77 $4,047 - $5,406
937 Added 1232.89%
1,013 $5,000
Q2 2023

May 20, 2024

SELL
$5.0 - $6.31 $315 - $397
-63 Reduced 45.32%
76 $0
Q2 2023

Aug 04, 2023

SELL
$5.0 - $6.31 $315 - $397
-63 Reduced 45.32%
76 $0
Q1 2023

May 20, 2024

SELL
$5.23 - $8.42 $439 - $707
-84 Reduced 37.67%
139 $0
Q1 2023

Apr 25, 2023

BUY
$5.23 - $8.42 $726 - $1,170
139 New
139 $0
Q3 2022

Nov 10, 2022

BUY
$10.02 - $26.15 $120 - $313
12 New
12 $0
Q1 2022

Apr 28, 2022

SELL
$5.96 - $7.61 $4,738 - $6,049
-795 Closed
0 $0
Q4 2021

Jan 20, 2022

SELL
$6.96 - $9.26 $278 - $370
-40 Reduced 4.79%
795 $6,000
Q3 2021

Nov 02, 2021

BUY
$5.71 - $7.39 $4,767 - $6,170
835 New
835 $6,000
Q2 2021

Aug 06, 2021

SELL
$6.1 - $7.58 $39,406 - $48,966
-6,460 Closed
0 $0
Q1 2021

Apr 23, 2021

SELL
$6.3 - $7.71 $9,702 - $11,873
-1,540 Reduced 19.25%
6,460 $42,000
Q2 2018

Jul 30, 2018

BUY
$5.89 - $7.29 $47,120 - $58,320
8,000 New
8,000 $47,000

Others Institutions Holding SIGA

About SIGA TECHNOLOGIES INC


  • Ticker SIGA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 73,024,096
  • Market Cap $471M
  • Description
  • SIGA Technologies, Inc., a commercial-stage pharmaceutical company, focuses on the health security and infectious disease markets in the United States. Its lead product is TPOXX, an oral formulation antiviral drug for the treatment of human smallpox disease caused by variola virus. SIGA Technologies, Inc. has a strategic partnership with Cipla T...
More about SIGA
Track This Portfolio

Track Parallel Advisors, LLC Portfolio

Follow Parallel Advisors, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Parallel Advisors, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Parallel Advisors, LLC with notifications on news.